Mode
Text Size
Log in / Sign up

Cervical squamous cell carcinoma

Part of Cancer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for cervical squamous cell carcinoma

15 trials tracked for cervical squamous cell carcinoma: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 1496 citations.

15Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 10 Phase 1 2
  1. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed · 1,496 cited
  2. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  3. Phase 3 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Completed
  4. Phase 2 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed
  5. Phase 2 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed
  6. Phase 2 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
Show 9 more trials
  1. Phase 2 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  2. Phase 2 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed
  3. Phase 2 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Completed
  4. Phase 2 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed
  5. Phase 2 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  6. Phase 2 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed
  7. Phase 2 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed
  8. Phase 1 Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Completed
  9. Phase 1 Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Transitioning from static TNM staging to a multidimensional, adaptive treatment model integrating genomics and immunology for HPV-associated OPSCC
Allergy & Immunology Sys. Review
Transitioning from static TNM staging to a multidimensional, adaptive treatment model integrating genomics and immunology for HPV-associated OPSCC Doctors are shifting from static staging to adaptive care for HPV throat cancer
This narrative review discusses the evolving management of HPV-associated oropharyngeal squamous cell carcinoma. The authors argue for trans…
Medical teams are moving away from old staging rules toward a new model that uses genomics and immunology for precise care.
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma
Oncology Meta-analysis
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma One Type of Cervical Cancer Is Far More Dangerous Than Others
This systematic review and meta-analysis synthesized comparative studies on HPV-independent and HPV-associated cervical adenocarcinoma. It f…
A large new analysis reveals that women with HPV-negative cervical adenocarcinoma face nearly three times the risk of death compared to thos…
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
Oncology Meta-analysis
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
SBRT plus atezolizumab shows activity in metastatic cervical cancer
OB/GYN & Women's Health Phase II
SBRT plus atezolizumab shows activity in metastatic cervical cancer Radiation plus immune therapy helps some patients with advanced cervical cancer survive longer
This prospective phase II trial evaluated SBRT followed by atezolizumab in 21 patients with metastatic, recurrent, or persistent cervical ca…
A small trial found that adding immune therapy to radiation helped some patients with advanced cervical cancer keep their disease stable for…
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
Pulmonology & Critical Care Meta-analysis
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Meta-analysis finds blood biomarkers predict outcomes in anal cancer but need validation
Gastroenterology Meta-analysis
Meta-analysis finds blood biomarkers predict outcomes in anal cancer but need validation Low blood counts and high inflammation may signal worse survival for anal cancer patients
This systematic review and meta-analysis of 3589 patients with anal squamous cell carcinoma found that elevated neutrophil-to-lymphocyte rat…
For patients with anal cancer, low hemoglobin and high inflammation markers linked to poorer survival in this analysis of nearly 3,600 peopl…
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
Oncology Cohort
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC Deep Heat Plus Drug Boosts Lung Cancer Response Rates
This retrospective cohort study of 100 patients with advanced squamous NSCLC evaluated deep hyperthermia combined with tislelizumab and chem…
Adding deep heat to standard lung cancer treatment improved response rates significantly while keeping safety levels the same as standard ch…
Disease progression and death in a 10 year old male with lower esophageal squamous cell carcinoma
Pediatrics Cohort
Disease progression and death in a 10 year old male with lower esophageal squamous cell carcinoma Rare case: child dies 7 months after esophageal cancer diagnosis
This case report and retrospective literature analysis describes a 10 year old male with lower esophageal squamous cell carcinoma.
A 10-year-old with a rare esophageal cancer died 7 months after diagnosis, highlighting the urgent need for better treatments.
Retrospective review finds higher ORR with salvage DCRT in locally advanced ESCC
Oncology Guideline
Retrospective review finds higher ORR with salvage DCRT in locally advanced ESCC Salvage therapy works better than upfront treatment for some esophageal cancer patients
This retrospective analysis of 91 patients from 3 medical centers compared salvage versus upfront definitive chemoradiotherapy (DCRT) for lo…
New data shows treating esophageal cancer after a failed first attempt may lead to better outcomes than starting with the strongest drugs im…
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Oncology Cohort
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer
Drug Pipeline Meta-analysis
Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer Do newer immunotherapies help people with advanced cervical cancer live longer?
This systematic review and network meta-analysis of phase III trials synthesized evidence on first-line immunotherapy regimens for persisten…
Newer immunotherapy combinations help people with advanced cervical cancer live longer and shrink tumors better than standard chemotherapy a…
Review of case report showing durable response after surgery in metastatic bladder SqCC
Palliative Care Guideline
Review of case report showing durable response after surgery in metastatic bladder SqCC She Was Offered Hospice. Surgery Gave Her Two More Years Instead
This narrative review synthesizes a single case report of a 65-year-old woman with metastatic squamous cell carcinoma of the bladder.
A woman with a rare, drug-resistant bladder cancer that had spread to both lungs chose surgery when hospice was offered — and two years late…